Author

James Lindsay 1

1 Digestive Di

DOWN REGULATION OF THE MICRORNA 200 FAMILY IN STRICTURED INTESTINAL RESECTION SPECIMENS FROM CROHN'S DISEASE PATIENTS INDICATES A ROLE FOR EPITHELIAL TO MESENCHYMAL TRANSITION

Shameer Mehta, Amy Lewis, Paolo Biancheri, Cleo Bishop, James Lindsay

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Severine Vermeire, Silvio Danese, Wen Zhou, Xuan Yao, Dapo Ilo, G Levy, Xavier Hebuterne, James O. Lindsay, Yuri Sanchez Gonzalez, Peter D.R. Higgins, Jean-Frédéric Colombel, Remo Panaccione

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

Remo Panaccione, Xavier Hebuterne, James Lindsay, Jianzhong Liu, Hiroshi Nakase, Geert D’Haens, Wangang Xie

Efficacy of upadacitinib as an induction therapy in severe and refractory ulcerative colitis: sub-group analysis of the phase 2b study U-ACHIEVE

Geert R. D'Haens, James Lindsay, Edward Loftus, Wen Zhou, Fabio Cataldi, Wangang Xie, David Pugatch, Remo Panaccione

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

Patrick F van Rheenen, Marina Aloi, Irit Avni-Biron, Katrine Carlsen, Rachel Cooney, Salvatore Cucchiara, Garret Cullen, Johanna Caroline Escher, Jaroslaw Kierkuś, James Lindsay, Eleftheria Roma, Richard K Russell, Joanna Sieczkowska, Marcus Harbord

FIVE-YEAR SAFETY DATA FROM THE OBSERVATIONAL POSTMARKETING ULCERATIVE COLITIS STUDY, A EUROPEAN REGISTRY FOR ADULTS WITH ULCERATIVE COLITIS TREATED WITH ORIGINATOR INFLIXIMAB OR STANDARD THERAPY

Julian Panés, James Lindsay, Niels Teich, Stefan Lindgren, Jean-Frederic Colombel, Freddy Cornillie, Heather Ann Flynn, Susan Huyck, Paul Stryszak, Ruji Yao, George Philip, Walter Reinisch

IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Kenji Watanabe, Laurent Peyrin-Biroulet, Silvio Danese, Kahaku Emoto, Yasushi Fujitani, Franck-Olivier Le-Brun, Alessandra Oortwijn, Tomohiro Ueno, James O. Lindsay, Gerhard Rogler, Toshifumi Hibi

INDICATORS OF SUBOPTIMAL THERAPY AMONG CROHN’S DISEASE PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS: RESULTS FROM A MULTINATIONAL STUDY

Alessandro Armuzzi, James Lindsay, Reema Mody, Bernd Bokemeyer, Javier Gisbert, Laurent Peyrin-Biroulet, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

INDUCTION AND MAINTENANCE TREATMENT WITH RISANKIZUMAB LEADS TO SYMPTOMATIC RELIEF IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Edouard Louis, Joana Torres, James O. Lindsay, Stefan Schreiber, Ryan Ungaro, Laimas Virginijus Jonaitis, Kristina Kligys, Stijn Van Haaren, Ezequiel Neimark, Javier Zambrano, Yafei Zhang, Geert R. D'Haens

INTERLEUKIN-17A HOMODIMER REDUCES PRO-INFLAMMATORY CYTOKINE PRODUCTION BY INFLAMMATORY BOWEL DISEASE MUCOSA CULTURED EX VIVO

Paolo Biancheri, Antonio Di Sabatino, Renata Curciarello, Paolo Giuffrida, Francesca Ammoscato, Gino Corazza, James Lindsay, Thomas Thornton MacDonald

Item 11 - 20 / 58
1
2
3 4 5 6